Trial Profile

A Phase 2, Multicenter, Randomized, Study of Trastuzumab Deruxtecan in Participants With HER2-overexpressing Locally Advanced, Unresectable or Metastatic Colorectal Cancer (DESTINY-CRC02)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 22 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

30 Apr 2025 Results assessing exploratory biomarker analysis (N=122 pts) were presented at the 116th Annual Meeting of the American Association for Cancer Research.
24 Apr 2025 According to Daiichi Sankyo Media release, Based on data from four phase 2 trials including HERALD,DESTINY-PanTumor02,DESTINY-CRC02 and DESTINY-Lung01,the company has submitted a supplemental New Drug Application (sNDA) to Japans Ministry of Health, Labour and Welfare (MHLW) for ENHERTU(trastuzumab deruxtecan) for the treatment of adult patients with HER2 positive advanced or recurrent solid tumors refractory or intolerant to standard treatments.
04 Nov 2024 Status changed from active, no longer recruiting to completed.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com